1.The Potential of Gallic Acid as a Radiosensitizer on Human Prostate Cancer: A Systematic Review of Preclinical Studies
Agung Tri Cahyono ; Melva Louisa ; Tiara Bunga Mayang Permata ; Handoko ; Endang Nuryadi ; Henry Kodrat ; Heri Wibowo ; Agus Rizal Ardy Hariandy Hamid ; Sri Mutya Sekarutami ; Soehartati Argadikoesoema Gondhowiardjo
Malaysian Journal of Medicine and Health Sciences 2021;17(No.2):246-254
Prostate adenocarcinoma accounts for majority of prostate cancer cases, and it was found to be highly radioresistant.
Gallic acid is a phenolic acid naturally occurring in many plants, reported to exhibit biological activities in eliminating cancer cell lines and xenografts. The purpose of this study is to review gallic acid as a potential radiosensitizer
agent in prostate cancer treatment. Article search was conducted in PubMed, EBSCO, and Scopus. 11 studies using
different cell lines including DU145, PC-3, LNCaP, and 22Rv1 xenograft of human prostate cancer were reviewed
in this paper. Gallic acid acts as a radiosensitizer mainly by increasing caspase-3 and caspase-9 activation resulting
in apoptosis, while also reducing intracellular CDKs, cyclins, and cdc25 phosphatases ultimately causing G2-M cell
cycle arrest. Gallic acid has a potential to be a new radiosensitizer compound in prostate cancer treatment. Additional clinical studies using gallic acid derivatives with lower hydrophilicity are needed.